Drug resistance in lung cancer
Harada, T.; Hara, N.
Nihon Rinsho. Japanese Journal of Clinical Medicine 60(Suppl 5): 317-321
2002
ISSN/ISBN: 0047-1852 PMID: 12101680 Document Number: 547651
Document emailed within 1 workday
Related Documents
Oguri, T.; Fujiwara, Y.; Ochiai, M.; Fujitaka, K.; Miyazaki, M.; Takahashi, T.; Yokozaki, M.; Isobe, T.; Ohune, T.; Tsuya, T.; Katoh, O.; Yamakido, M. 1998: Expression of lung-resistance protein gene is not associated with platinum drug exposure in lung cancer Anticancer Research 18(6a): 4159-4162Saijo, N.; Nishio, K.; Yoshida, M. 1998: Overcoming drug resistance in lung cancer Oncology 12(1 Suppl 2: 87-89
Wu, Q.-g.; Cao, T.-t.; Cheng, Z.; Wang, J. 2011: Effects of Akt2-siRNA on chemotherapeutic sensitivity and drug resistance in human lung cancer cells Zhonghua Yi Xue Za Zhi 91(30): 2139-2142
Gao, Z.; Gao, Z.; Fields, J.Z.; Boman, B.M. 1998: Co-transfection of MDR1 and MRP antisense RNAs abolishes the drug resistance in multidrug-resistant human lung cancer cells Anticancer Research 18(4c): 3073-3076
Paterson, J.; Uriel, C.; Egron, M.J.; Herscovici, J.; Antonakis, K.; Alaoui-Jamali, M.A. 1998: Antiproliferative and apoptotic activities of ketonucleosides and keto-C-glycosides against non-small-cell lung cancer cells with intrinsic drug resistance Antimicrobial Agents and ChemoTherapy 42(4): 779-784
Volm, M.; Bak, M.; Mattern, J. 1988: Intrinsic drug resistance in a human lung carcinoma xenograft is associated with overexpression of multidrug-resistance DNA-sequences and of plasma membrane glycoproteins Arzneimittel-Forschung 38(8): 1189-1193
Fujita, F.; Fujita, M.; Fujita, M.; Sakamoto, Y. 1994: Acquired resistance and cross-resistance of gemcitabine to cisplatin or vindesine in human lung cancer xenografted in nude mice Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(16): 2749-2755
Keizer, H.G.; Schuurhuis, G.J.; Broxterman, H.J.; Lankelma, J.; Schoonen, W.G.; van Rijn, J.; Pinedo, H.M.; Joenje, H. 1989: Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells Cancer Research 49(11): 2988-2993
Baas, F.; Jongsma, A.P.; Broxterman, H.J.; Arceci, R.J.; Housman, D.; Scheffer, G.L.; Riethorst, A.; van Groenigen, M.; Nieuwint, A.W.; Joenje, H. 1990: Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line Cancer Research 50(17): 5392-5398
Aoe, K.; Hiraki, A.; Murakami, T.; Maeda, T.; Umemori, Y.; Katayama, H.; Eda, R.; Takeyama, H. 2005: Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy Anticancer Research 25(1b): 415-418
de la Torre, M.; Hao, X.Y.; Larsson, R.; Nygren, P.; Tsuruo, T.; Mannervik, B.; Bergh, J. 1993: Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases Anticancer Research 13(5a): 1425-1430
Pillay, D.; Albert, J.; Bertagnolio, S.; Boucher, C.; Brun-Vezinet, F.; Clotet, B.; Giaquinto, C.; Perno, C.F. 2013: Implications of HIV drug resistance on first- and second-line therapies in resource-limited settings: report from a workshop organized by the Collaborative HIV and Anti-HIV Drug Resistance Network Antiviral Therapy 18(6): 831-836
Hamers, R.L.; Schuurman, R.; Sigaloff, K.C.E.; Wallis, C.L.; Kityo, C.; Siwale, M.; Mandaliya, K.; Ive, P.; Botes, M.E.; Wellington, M.; Osibogun, A.; Wit, F.W.; van Vugt, M.èl.; Stevens, W.S.; de Wit, T.F.R. 2012: Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study LANCET. Infectious Diseases 12(4): 307-317
Michowitz, M.; Dayan-Avidan, G.; Bar-Shira-Maymon, B.; Donin, N.; Leibovici, J. 1994: Drug resistance and its counteraction by cyclosporin A in function of metastatic potential in the Lewis lung carcinoma system Cellular and Molecular Biology 40(4): 551-560
Choy, B.K.; McClarty, G.A.; Chan, A.K.; Thelander, L.; Wright, J.A. 1988: Molecular mechanisms of drug resistance involving ribonucleotide reductase: hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations Cancer Research 48(8): 2029-2035
Takeda, K. 2009: Overcoming resistance to EGFR-TKi in lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(4): 552-556
Ochiya, T. 2010: Novel mechanisms of drug resistance in cancer Seikagaku. Journal of Japanese Biochemical Society 82(1): 34-38
Bertagnolio, S.; Rodriguez-Diaz, R.A.; Fuentes-Romero, L.L.; Bennett, D.E.; Viveros-Rogel, M.; Hart, S.; Pilon, R.; Sandstrom, P.; Soto-Ramirez, L.E. 2012: Transmitted HIV drug resistance among drug-naive subjects recently infected with HIV in Mexico City: a World Health Organization survey to classify resistance and to field test two alternative patient enrollment methods Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 54(Suppl 4): S328-S333
Watzka, S.B.; Posch, F.; Hochmair, M.; Setinek, U.; Köstler, W.J.; Müller, M.R. 2011: Resistance to EGFR targeting therapies in lung cancer Minerva Chirurgica 66(5): 483-494
He, Y.; Liu, Y.-g.; Cen, S.; Zhou, J.-m. 2015: The mechanisms of drug resistance in prostate cancer Yao Xue Xue Bao 50(7): 797-801